Oxiglutatione

CHEMBL1372 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
612.6 g/mol
LogP
-9.1
Phase
4

A form of glutathione (the reduced tripeptide) used topically in eye drops to protect the corneal epithelium during ocular procedures and to treat conditions associated with oxidative stress in the eye. It acts as an antioxidant, neutralizing reactive oxygen species that can damage eye tissue.

น้ำหนักโมเลกุล

612.6000 g/mol

LogP

-9.10

TPSA

368.00 Ų

Lipinski RO5

ไม่ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O

InChI

InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1

Molecular Formula

C20H32N6O12S2

HBD / HBA

10 / 16

พันธะที่หมุนได้

21

อะตอมหนัก

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A form of glutathione (the reduced tripeptide) used topically in eye drops to protect the corneal epithelium during ocular procedures and to treat conditions associated with oxidative stress in the eye. It acts as an antioxidant, neutralizing reactive oxygen species that can damage eye tissue.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Oxiglutatione is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1372. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 65359. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.